Genitourinary Cancers

Uro Pipeline: FDA accepts priority review application for RCC treatmentAgents for bladder cancer, prostate cancer, and stress urinary incontinence are also included in this round-up of pipeline developments.
‘BCG-unresponsive’ definition bolstered by studyPatients with bacillus Calmette-Guérin-unresponsive bladder cancer had worse clinical outcomes than patients who relapsed but did not meet BCG-unresponsive criteria, according to results of a retrospective analysis presented at the 2017 Society of Urologic Oncology annual meeting in Washington.
BLC scores well against WLC in recurrent bladder tumorsFluorescent blue light cystoscopy improves 3-year recurrence-free survival rates in patients with recurrent bladder tumors compared to white light cystoscopy, and researchers believe its use should be expanded.
Role of blue light cystoscopy to detect bladder cancer"Numerous clinical studies have exhibited significantly improved tumor detection rates with BLC," write Zachary L. Smith, MD, and Norm D. Smith, MD.
Top 5 bladder cancer articles of 2017A look at Urology Times' most-read articles on bladder cancer reveals a variety of topics, ranging from radical cystectomy to the role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance.
[Quiz] Abdominal pain after laparoscopic nephrectomyA 46-year-old male underwent a left laparoscopic radical nephrectomy for a cT1b renal cell carcinoma. Intra-operatively, a rent in the descending mesocolon was made during bowel mobilization but was not closed. Subsequently, the patient presented to the emergency room 4 days later with complaints of sudden onset sharp abdominal pain and nausea. A non-contrast computed tomography scan was obtained. What is the diagnosis?
Uro Pipeline: NDA submitted for non-metastatic castration-resistant PCa agentOther pipeline products discussed in this round-up include and advanced renal cell carcinoma agent, a bladder cancer detection agent, and a BPH treatment.
How to reduce opioid use in post-op patientsIn this interview, urologist Francis J. McGovern, MD, discusses the scope of the problem of opioid abuse, outlines opioid-sparing strategies, and explains what the future holds in this area.
Immediate post-TURBT mitomycin instillation reduces recurrence riskMitomycin C instillation within 24 hours after transurethral resection of non-muscle invasive bladder cancer significantly reduces the risk of recurrence and delays the time to recurrence.
Testis cancer patients fare poorly under ACASince passage of the Affordable Care Act, the number of testicular cancer patients with insurance has dwindled, while rates of advanced testis cancer have climbed, according to a recent study.